Document Detail


The aryl hydrocarbon receptor predisposes hepatocytes to Fas-mediated apoptosis.
MedLine Citation:
PMID:  15550680     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Liver homeostasis is achieved by the removal of diseased and damaged hepatocytes and their coordinated replacement to maintain a constant liver cell mass. Cirrhosis, viral hepatitis, and toxic drug effects can all trigger apoptosis in the liver as a means of removing the unwanted cells, and the Fas "death receptor" pathway comprises a major physiological mechanism by which this occurs. The susceptibility to Fas-mediated apoptosis is, in part, a function of the hepatocyte's proteome. The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor known to influence apoptosis, conceivably by regulating the expression of genes involved in apoptotic signaling. In this article, we present evidence demonstrating that AhR expression and function promote apoptosis in liver cells in response to Fas stimulation. Reintroduction of the AhR into the AhR-negative BP8 hepatoma cells as well as into primary hepatocytes from AhR knockout mice increases the magnitude of cell death in response to Fas ligand. Enhanced apoptosis correlates with increased caspase activity and mitochondrial cytochrome c release but not with the expression of several Bcl-2 family proteins. In vivo studies showed that in contrast to wild-type mice, AhR knockout mice are protected from the lethal effects of the anti-Fas Jo2 antibody. Moreover, down-regulation of the aryl hydrocarbon receptor nuclear translocator protein in vivo by adenovirus-mediated RNA interference to suppress AhR activity provided wild-type mice partial protection from Jo2-induced lethality.
Authors:
Kyung-Tae Park; Kristen A Mitchell; Gengming Huang; Cornelis J Elferink
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2004-11-18
Journal Detail:
Title:  Molecular pharmacology     Volume:  67     ISSN:  0026-895X     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-02-18     Completed Date:  2005-04-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  612-22     Citation Subset:  IM    
Affiliation:
Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1031, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antigens, CD95 / physiology*
Apoptosis / physiology*
Carcinoma, Hepatocellular
Cell Line, Tumor
Fas Ligand Protein
Hepatocytes / cytology*,  physiology
Liver Neoplasms
Membrane Glycoproteins / deficiency,  physiology
Mice
Mice, Knockout
Receptors, Aryl Hydrocarbon / deficiency,  genetics,  physiology*
Reverse Transcriptase Polymerase Chain Reaction
Grant Support
ID/Acronym/Agency:
ES06676/ES/NIEHS NIH HHS; F32-ES013588/ES/NIEHS NIH HHS; R01-ES07800/ES/NIEHS NIH HHS; T32-ES07254/ES/NIEHS NIH HHS
Chemical
Reg. No./Substance:
0/Antigens, CD95; 0/Fas Ligand Protein; 0/Fasl protein, mouse; 0/Membrane Glycoproteins; 0/Receptors, Aryl Hydrocarbon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorti...
Next Document:  Protease inhibitors in spontaneous cervical artery dissections.